TH:CC News and Press, Theratechnologies Inc.

Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...

Firan Technology Group Corporation (FTG:CA) is expected to report for Q2 2024 Theratechnologies Inc. (TH:CA) is expected to report for Q2 2024 Transat A.T. Inc. Voting and Variable Voting Shares (TRZ:CA) is expected to report $-0.66 for Q2 2024

MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...

Poster highlights durable disease stabilization lasting beyond treatment completion Results suggest a unique, multimodal mechanism of action that differs from other cancer therapeutics Favorable tolerability sets stage for Part 3 (dose optimization) of Phase 1 trial, already u...

First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechno...

MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company h...

MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company&#...

Q1 2024 consolidated revenue of $16.2 million Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA 1 FY2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13-15 million Acceler...

Postmedia Network Canada Corp. Class C Voting Shares (PNC.A:CA) is expected to report for Q2 2024 Goodfood Market Corp. (FOOD:CA) is expected to report $-0.04 for Q2 2024 Platinum Group Metals Ltd. (PTM:CA) is expected to report for Q2 2024 North West Company Inc. (The) (NWC:CA) is ex...

Novel camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft models SORT1 gene silencing results in drastic decrease in peptide-drug conjugate uptake which supports a SORT1-me...